Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb:308:114347.
doi: 10.1016/j.psychres.2021.114347. Epub 2021 Dec 20.

A scoping review of the use of cannabidiol in psychiatric disorders

Anna E Kirkland  1 , Matthew C Fadus  2 , Staci A Gruber  3 , Kevin M Gray  4 , Timothy E Wilens  5 , Lindsay M Squeglia  4
Affiliations

A scoping review of the use of cannabidiol in psychiatric disorders

Anna E Kirkland et al. Psychiatry Res. 2022 Feb.

Abstract

Cannabidiol (CBD) has become a fast-growing avenue for research in psychiatry, and clinicians are challenged with understanding the implications of CBD for treating mental health disorders. The goal of this review is to serve as a guide for mental health professionals by providing an overview of CBD and a synthesis the current evidence within major psychiatric disorders. PubMed and PsycINFO were searched for articles containing the terms "cannabidiol" in addition to major psychiatric disorders and symptoms, yielding 2952 articles. Only randomized controlled trials or within-subject studies investigating CBD as a treatment option for psychiatric disorders (N = 16) were included in the review. Studies were reviewed for psychotic disorders (n = 6), anxiety disorders (n = 3), substance use disorders (tobacco n = 3, cannabis n = 2, opioid n = 1), and insomnia (n = 1). There were no published studies that met inclusion criteria for alcohol or stimulant use disorder, PTSD, ADHD, autism spectrum disorder, or mood disorders. Synthesis of the CBD literature indicates it is generally safe and well tolerated. The most promising preliminary findings are related to the use of CBD in psychotic symptoms and anxiety. There is currently not enough high-quality evidence to suggest the clinical use of CBD for any psychiatric disorder.

Keywords: Anxiety; CBD; Clinicians; Psychiatry; Psychosis; Treatment.

PubMed Disclaimer

References

    1. Achenbach JC, Hill J, Hui JP, Morash MG, Berrue F, Ellis LD, 2018. Analysis of the uptake, metabolism, and behavioral effects of cannabinoids on zebrafish larvae. Zebrafish 15 (4), 349–360. - PubMed
    1. Ahmed KT, Amin MR, Shah P, Ali DW, 2018. Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (Δ 9-tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation. Scientific reports 8 (1), 1–14. - PMC - PubMed
    1. Alharbi YN, 2020. Current legal status of medical marijuana and cannabidiol in the United States. Epilepsy & Behavior 112, 107452. - PubMed
    1. Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, 2014. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA psychiatry 71 (3), 281–291. - PubMed
    1. Azer V, Blackledge J, Charlres A, Chen O, Kernan J, Nadeau P, Neivert C, Osborne J, Rhyee C, Schenkel D, 2019. Cowen’s Collective View of CBD. Cowen’s Research.

Publication types

MeSH terms